Skip to content

Study · Case report or series · n = 1 · 2020

1 result

Melanotan II: a possible cause of renal infarction: review of the literature and case report.

Peters B, Hadimeri H, Wahlberg R, Afghahi H

CEN case reports18 Jan 2020Cited by 4 (Europe PMC)

PMID31953620 (opens in a new tab)PMCIDPMC7148395 (opens in a new tab)DOI10.1007/s13730-020-00447-z (opens in a new tab)PepBankPUB-31953620
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a case report, renal infarction was most likely attributed to melanotan II.

    In plain wordsIn one reported case, a kidney infarction was most likely linked to melanotan II use.

    Peptide
    Melanotan II
    Outcome
    IncreaseRenal infarction
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    including a case of a renal infarction most likely attributed to Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.